Skip to main content

Tonix Pharmaceuticals Holding Corp 10-Q for FY2026 Q3

Tonix Pharmaceuticals Holding Corp. (TNXP)

10-Q 2026-11-09 For: 2026-09-30
View Original
Added on November 09, 2026

About this 10-Q

Tonix Pharmaceuticals Holding Corp filed this 10-Q on November 9, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Tonix Pharmaceuticals Holding Corp. reported $37.7 million of nine-month 2026 revenue after launching TONMYA, alongside a $134.1 million net loss. Resources are expected to last into early third quarter of 2027, with substantial doubt about its going concern. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$17.23M
up 423.8% from $3.29M a year earlier
Net loss
$53.33M
compared with a net loss of $32.01M a year earlier
Diluted EPS
-$2.89
compared with -$3.59 a year earlier